How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program

Current Cardiology Reports

Volumn 18, Issue 12, 2016, Pages

  Shah, Sanjiv J ^a   Cogswell, Rebecca ^b   Ryan, John J ^c   Sharma, Kavita ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Diagnosis; Disease management program; Heart failure with preserved ejection fraction; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MIDODRINE; SPIRONOLACTONE; ANGIOTENSIN RECEPTOR; CARDIOVASCULAR AGENT;

CLINICAL PROGRAM; HEALTH CARE CONCEPTS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; MEDICAL STAFF; MORBIDITY; MORTALITY; PATIENT CARE; PATIENT IDENTIFICATION; PREVALENCE; REIMBURSEMENT; REVIEW; ATRIAL FIBRILLATION; COMPLICATION; HEART FAILURE; METABOLISM; PATHOPHYSIOLOGY; PROGRAM DEVELOPMENT; PROGRAM EVALUATION;

ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; PREVALENCE; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RECEPTORS, ANGIOTENSIN;

EID: 84993982768     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-016-0802-1     Document Type: Review

References (44)

1. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10(4):401–10.
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.
3. ••Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134(1):73–90. This paper is a state of the art review on the current approach to treatment of HFpEF. Essential background reading for anyone interested in starting a HFpEF clinic.
4. Shah SJ, Katz DH, Deo RC. Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10(3):407–18.
5. Jaarsma T, van der Wal MH, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168(3):316–24.
6. Meijers WC, Hoekstra T, Jaarsma T, van Veldhuisen DJ, de Boer RA. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24(4):287–95. This investigation, a secondary analysis of the multicenter COACH trial, which examined the efficacy of HF clinics, shows that natriuretic peptide levels are within the “normal” range in 30% of patients and that HFpEF patients makeup a very small part of current HF clinics.
7. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol. 2012;60(23):2349–56.
8. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.
9. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
10. Unzek S, Popovic ZB, Marwick TH. Effect of recommendations on interobserver consistency of diastolic function evaluation. J Am Coll Cardiol Img. 2011;4(5):460–7.
11. Anjan VY, Loftus TM, Burke MA, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110(6):870–6.
12. Kitzman DW, Shah SJ. The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol. 2016;68(2):200–3.
13. Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47(4):742–8.
14. Shah SJ. Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter. J Am Coll Cardiol. 2013;62(15):1339–42.
15. Gustafsson F, Arnold JM. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J. 2004;25(18):1596–604.
16. Thomas R, Huntley A, Mann M, et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart. 2013;99(4):233–9.
17. Burke MA, Katz DH, Beussink L, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7(2):288–99.
18. Burkhoff D, Maurer MS, Joseph SM, et al. Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. JACC Heart Fail. 2015;3(4):275–82.
19. Freed BH, Daruwalla V, Cheng JY, et al. Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain. Circ Cardiovasc Imaging. 2016;9(3):1–10.
20. Katz DH, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol. 2013;112(8):1158–64.
21. Katz DH, Burns JA, Aguilar FG, Beussink L, Shah SJ. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail. 2014;2(6):586–96.
22. Klein DA, Katz DH, Beussink-Nelson L, Sanchez CL, Strzelczyk TA, Shah SJ. Association of chronic kidney disease with chronotropic incompetence in heart failure with preserved ejection fraction. Am J Cardiol. 2015;116(7):1093–100.
23. Selvaraj S, Ilkhanoff L, Burke MA, et al. Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction. J Am Soc Echocardiogr. 2014;27(1):74–82.e72.
24. Selvaraj S, Klein I, Danzi S, Akhter N, Bonow RO, Shah SJ. Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110(2):234–9.
25. Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269–79. This paper shows the heterogeneity of the HFpEF syndrome, a major reason why it is under-diagnosed. This paper also describes the Northwestern HFpEF program in detail, and is an example of the research performed using data from patients enrolled in the program.
26. Unger ED, Dubin RF, Deo R, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18(1):103–12.
27. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.
28. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373(24):2314–24.
29. Hirschberg J, Manning CD. Advances in natural language processing. Science. 2015;349(6245):261–6.
30. Nadkarni PM, Ohno-Machado L, Chapman WW. Natural language processing: an introduction. J Am Med Inform Assoc. 2011;18(5):544–51.
31. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–6.
32. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539–50.
33. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588–95.
34. Oktay AA, Shah SJ. Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. Curr Cardiol Rev. 2015;11(1):42–52. This review article provides practical advice on how to diagnose and treat HFpEF, with pearls that can be quite helpful to those considering starting their own HFpEF program.
35. Chen LY, Lopez FL, Gottesman RF, et al. Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. Stroke. 2014;45(9):2568–74.
36. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA. 2008;300(4):431–3.
37. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005.
38. Oktay AA, Shah SJ. Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. Curr Cardiol Rep. 2014;16(12):545.
39. Mitter SS, Shah SJ. Spironolactone for management of heart failure with preserved ejection fraction: Whither to After TOPCAT? Curr Atheroscler Rep. 2015;17(11):64.
40. Pfeffer MA, Braunwald E. Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiol. 2016;1(1):7–8.
41. Flatt DM, Brown MC, Mizeracki AM, King BJ, Weber KT. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review. JAMA Cardiol. 2016. (in press).
42. Sharma K, Hill T, Grams M, et al. Outcomes and worsening renal function in patients hospitalized with heart failure with preserved ejection fraction. Am J Cardiol. 2015;116(10):1534–40.
43. Arend J, Tsang-Quinn J, Levine C, Thomas D. The patient-centered medical home: history, components, and review of the evidence. Mt Sinai J Med. 2012;79(4):433–50.
44. Jackson GL, Powers BJ, Chatterjee R, et al. Improving patient care. The patient centered medical home. A Systematic Review. Ann Intern Med. 2013;158(3):169–78.